Optimizing investigator-led oncology research in Europe - PubMed (original) (raw)

Editorial

Optimizing investigator-led oncology research in Europe

Tiziano Barbui et al. Haematologica. 2012 Jun.

No abstract available

1. Commission of the European Communities. Regulation (EC) n. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. 2009. [accessed Dec 9, 2011]. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726_cons/reg_20....
1. Council of the European Communities. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal of the European Union. 1989;L040:8–11.
1. Ridley DB. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet. 2010;376(9744):922–7. - PubMed
1. Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess. 2005;1 Doc 09. - PMC - PubMed
1. European Federation of Pharmaceutical Industries and Associations. Patients W.A.I.T. indicator: 2010 report – based on EFPIA’s database (first EU marketing authorisation in the period 2007-’09) [accessed Dec 9, 2011]. http://www.efpia.eu/content/default.asp?PageID=559&DocID=10200.